drugset / Trial / NCT04818346
A Study to Evaluate the Efficacy and Safety of INCB054707 in Participants With Vitiligo
RandomizedParallel-groupTriple-blindTreatment
Summary
The purpose of this study is to evaluate the efficacy and safety of INCB054707 over a 24-week placebo-controlled double-blind treatment period, followed by a 28-week double-blind extension period in participants with nonsegmental vitiligo.
Timeline
- Start
- 2021-05-06
- Primary completion
- 2022-05-24
- Completion
- 2023-05-24
Publications
- Passeron T, Pandya AG, Ezzedine K, van Geel N, Erskine L, Santos LL, Xue Z, Blauvelt A. Post Hoc Subgroup and Body Region Analyses of VASI Outcomes Among Patients with Vitiligo in a Phase 2 Povorcitinib Trial. Adv Ther. 2026 Jul 13. doi: 10.1007/s12325-026-03673-6. Online ahead of print.
- Pandya AG, Ezzedine K, Passeron T, van Geel N, Brown K, Santos LL, Erskine L, Wagya K, Blauvelt A. Efficacy and safety of the oral Janus kinase 1 inhibitor povorcitinib in patients with extensive vitiligo in a phase 2, randomized, double-blinded, dose-ranging, placebo-controlled study. J Am Acad Dermatol. 2025 Oct;93(4):946-955. doi: 10.1016/j.jaad.2025.06.027. Epub 2025 Jun 13.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Povorcitinib | Small molecule | 15 mg | — |
| Subject | Povorcitinib | Small molecule | 45 mg | — |
| Subject | Povorcitinib | Small molecule | 75 mg | — |